AstraZeneca sells US rights to four drugs for $46.5m
AstraZeneca has sold the US rights and New Drug Applications to four drugs to ANI Pharmaceuticals, a speciality pharmaceutical company.
Announced on Friday, December 29, the deal will see ANI acquire the rights for $46.5 million in cash, royalties, and sales-based milestones.
AstraZeneca will continue to market Atacand (candesartan), Atacand HCT, Arimidex (anastrozole) and Casodex (bicalutamide) outside of the US.
Atacand and Atacand HCT are used to treat hypertension. Arimidex is used to treat breast cancer, while Casodex is used to treat prostate cancer.
Collectively, the products generated approximately $19 million in US market sales during the 12 months through October 2017, according to IMS Health.
Arthur Przybyl, ANI’s president and CEO, said: “This acquisition complements our brand and generic strategies and further expands and diversifies our commercial portfolio.”
In November, AstraZeneca and the Chinese Future Industry Investment Fund (FIIF) partnered to establish a company focused on discovering, developing and commercialising new medicines.
The company, Dizal Pharmaceutical, holds exclusive rights to develop and commercialise three potential medicines currently in pre-clinical development from AstraZeneca’s pipeline in its main therapy areas of oncology, cardiovascular and metabolic diseases, and respiratory.
Then, in December, LSIPR reported that AstraZeneca invested £500 million in its new research and development centre and global headquarters in Cambridge, UK.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories like this sent straight to your inbox.
